Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease

CVT-301 (Inbrija) is a self-administered orally inhaled levodopa approved for the intermittent treatment of OFF episodes in patients with Parkinson's disease (PD) treated with carbidopa/levodopa. Prior studies only evaluated CVT-301 after the first ON of the day. The objective of this study was...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Parkinsonism & related disorders 2019-07, Vol.64, p.175-180
Hauptverfasser:	Hauser, Robert A., Isaacson, Stuart H., Ellenbogen, Aaron, Safirstein, Beth E., Truong, Daniel D., Komjathy, Steven F., Kegler-Ebo, Deena M., Zhao, Ping, Oh, Charles
Format:	Artikel
Sprache:	eng
Schlagworte:	Carbidopa CVT-301 Inbrija Inhalation Levodopa OFF periods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!